Australia’s CSL agrees to buy Novartis’ influenza vaccine business for $275m
The latest acquisition will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. The transaction requires regulatory approvals and is expected to be completed in the second
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.